Mabthera: Clinical Trials

80 trials of Mabthera, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

42 completed, 13 active not recruiting, 12 terminated, 6 recruiting. 80 Phase 3, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 380Completed 42, Active not recruiting 13, Terminated 12, Recruiting 6, Unknown 6, Withdrawn 1
Phase 28Completed 4, Active not recruiting 2, Recruiting 1, Unknown 1

Follow Mabthera: new trials by email Literature Review of Mabthera trials Research Report on Mabthera

Trials (filtered) newest first · largest first

All 80 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)2712027-07-272026-11-17
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
Biospecimen Collection, Computed Tomography, Cyclophosphamide - Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
Phase 3RecruitingSWOG Cancer Research Network1022026-08-042026-10-13
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
Rituximab, Tocilizumab, Tofacitinib - Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris422025-06-062026-04-03
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Biospecimen Collection, Computed Tomography, Mosunetuzumab - Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Phase 3RecruitingNational Cancer Institute (NCI)6002024-10-232026-11-18
Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders
Rituximab infusion, Placebo infusion, Premedications - Anti-MAG Neuropathy
Phase 3RecruitingCentre Hospitalier Universitaire de Saint Etienne902023-06-292025-11-24
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Rituximab - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Phase 3RecruitingAmsterdam UMC, location VUmc2002023-04-012023-04-28
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 3Active not recruitingChildren's Oncology Group662023-03-152026-07-30
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
Rituximab, Placebo - Polymyalgia Rheumatica
Phase 3Active not recruitingSint Maartenskliniek1742023-02-092026-02-04
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed
Rituximab, Placebo - Polymyalgia Rheumatica
Phase 3CompletedSint Maartenskliniek1142023-02-012026-02-03
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Zanubrutinib, Rituximab, Lenalidomide - Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Phase 3Active not recruitingBeOne Medicines7992022-03-102026-10-15
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
Rituximab, Placebo - Myasthenia Gravis, Generalized
Phase 3UnknownFondazione Policlinico Universitario Agostino Gemelli IRCCS402022-02-282025-08-01
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Primary Mediastinal Large B-Cell Lymphoma
Phase 3Active not recruitingNational Cancer Institute (NCI)2442021-10-052026-11-04
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Pirtobrutinib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3Active not recruitingLoxo Oncology, Inc.2822021-09-232026-09-25
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Pirtobrutinib, Venetoclax, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3Active not recruitingLoxo Oncology, Inc.6002021-09-202026-01-29
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Zandelisib, Rituximab, Bendamustine - Follicular Lymphoma (FL), Non Hodgkin Lymphoma
Phase 3TerminatedMEI Pharma, Inc.822021-08-132024-11-04
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma
Phase 2 / Phase 3Active not recruitingNational Cancer Institute (NCI)4222021-05-202026-11-12
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
Polatuzumab Vedotin, Mabthera, Ifosfamide - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 3CompletedGWT-TUD GmbH3062021-04-302026-06-10
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
Rituximab, Ocrelizumab - Relapsing Remitting Multiple Sclerosis
Phase 3Active not recruitingHaukeland University Hospital2142020-11-022025-06-27
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
Obinutuzumab, Venetoclax, Fludarabine - Chronic Lymphocytic Leukemia (CLL)
Phase 3CompletedHoffmann-La Roche1662020-05-282026-03-03
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 2 / Phase 3Active not recruitingNational Cancer Institute (NCI)3632019-10-222026-11-12

Showing 20 of 80. Sign in to see all of them.

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (14)  ·  Lymphoma, Non-Hodgkin (12)  ·  Lymphoma, Follicular (9)  ·  Lymphoma, Large B-Cell, Diffuse (7)  ·  Lymphoma (5)  ·  Lymphoma, B-Cell, Marginal Zone (5)  ·  Lymphoma, B-Cell (4)  ·  Lymphoma, Mantle-Cell (4)  ·  Multiple Sclerosis, Relapsing-Remitting (4)  ·  Arthritis, Rheumatoid (3)  ·  Lupus Nephritis (3)  ·  Anemia (2)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2)  ·  Burkitt Lymphoma (2)  ·  Granulomatosis with Polyangiitis (2)

Sponsors

Hoffmann-La Roche (9)  ·  National Cancer Institute (NCI) (9)  ·  The Lymphoma Academic Research Organisation (4)  ·  University Hospital, Tours (4)  ·  German CLL Study Group (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Genentech, Inc. (2)  ·  Haukeland University Hospital (2)  ·  Imperial College London (2)  ·  Loxo Oncology, Inc. (2)  ·  SecuraBio (2)  ·  Sint Maartenskliniek (2)  ·  University Hospital, Rouen (2)  ·  Amsterdam UMC, location VUmc (1)  ·  Anders Svenningsson (1)

Countries

United States (28)  ·  France (26)  ·  Italy (18)  ·  Canada (17)  ·  Australia (16)  ·  Spain (14)  ·  Germany (13)  ·  United Kingdom (13)  ·  Belgium (11)  ·  Sweden (11)  ·  Brazil (10)  ·  Poland (10)  ·  Austria (8)  ·  Hungary (8)  ·  Netherlands (8)

Top investigators

Hagop Youssoufian, MD (2)  ·  Aatke van der Maas (1)  ·  Aatke van der Maas, MD PhD (1)  ·  Anders Svenningsson, MD, PhD (1)  ·  Anders Svenningsson, Professor (1)  ·  Andrew Pettitt, Professor (1)  ·  Barbara Eichhorst, MD (1)  ·  Barbara Eichhorst, MD, Prof. (1)  ·  Benjamin Terrier, MD, PhD (1)

Results publications

PMID 27695295, PMID 39400109, PMID 39513526, PMID 17687130, PMID 20039413, PMID 20841509, PMID 22231479, PMID 23101480, PMID 24002601, PMID 24265828, PMID 24521993, PMID 24591201, PMID 24720836, PMID 24895339, PMID 25343233, PMID 25686644, PMID 26555944, PMID 26712227, PMID 26867033, PMID 26875824, PMID 28031173, PMID 28251914, PMID 28270229, PMID 28476440, PMID 29061568, PMID 29275118, PMID 30010481, PMID 30089664, PMID 30184451, PMID 30501481, PMID 30719632, PMID 30770362, PMID 30811293, PMID 30837635, PMID 30934066, PMID 31184752, PMID 31365801, PMID 31573078, PMID 31729982, PMID 31806605, PMID 32071431, PMID 32589970, PMID 32601378, PMID 32673385, PMID 32810220, PMID 33097974, PMID 33211799, PMID 33288485, PMID 33439748, PMID 33649098

NIH funding

U10CA021115 (3), U10CA180820 (3), U10CA180821 (3), U10CA180888 (3), 2008 (2), 2014 (2), U10CA180886 (2), U24CA196172 (2), UL1RR024150 (2), 2005 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), 2023 (1)